Doximity, Inc. · NYSE:DOCS

Doximity — Investor Presentation (November 2022)

18 slides from Doximity's investor presentation, November 2022

  1. Slide 1: Investor Presentation Fall/Winter 2022

    INVESTOR PRESENTATION Fall/Winter 2022

  2. Slide 2: Legal Disclaimer

    LEGAL DISCLAIMER This presentation and associated commentary may contain forward-looking statements, including statements regarding expectations of future results of operations or financial performance of Doximity, market size and growth opportunities, the calculation of certain of our key financial

  3. Slide 3: The Digital Platform for Doctors

    THE DIGITAL PLATFORM FOR DOCTORS Leading Network Blue Chip Clients Growth and Profit 80%+ 20/20 35% Top Hospitals of all U.S. and Health Systems Subscription Physicians1 Top Pharmaceutical Revenue Growth5 Manufacturers3 370K+ 128% 43% Telehealth Unique Net Revenue Adj. EBITDA Active Providers2 Retent

  4. Slide 4: Glaring Day-to-Day Inefficiencies

    GLARING DAY-TO-DAY INEFFICIENCIES 80% of US HC documents sent via snail mail and fax1 78% of physicians report burnout, with health IT as one of least satisfying factors2 1. Keeping it Together Issue Brief on Exchanging Medical Documentation CAQH Nov 2020. Does not include email. 2. 2018 Survey of A

  5. Slide 5: Bringing Tech to Medicine

    BRINGING TECH TO MEDICINE Inspired by enterprise tech Purpose-built for healthcare Networking Professional Network Professional Profiles, Search, Colleague Connectivity, Career Management News Newsfeed eSignatures Medical Articles & News, Peer Updates, Clinical Discussions, CME Credit, Sponsored Cont

  6. Slide 6: Purpose Built for Healthcare

    PURPOSE BUILT FOR HEALTHCARE Professional Network Newsfeed Productivity Proprietary 6 Watch Product Demo

  7. Slide 7: Our Commercial Solutions

    OUR COMMERCIAL SOLUTIONS Marketing Hiring Telehealth Educate on Latest News & Treatments Uncover Passive Candidates Reduce No-Shows & Leakage Relevance and personalization drive Rx’s & Referrals Find specialized talent #1 “Best in KLAS” Telehealth Video Conferencing 1. Based on “Best in KLAS” Telehe

  8. Slide 8: Marketing Solutions

    MARKETING SOLUTIONS Largest Revenue Driver: Marketing Solutions Health Systems 2 17:1 ROI LexisNexis Leading Network Subscription Pricing Model Pharma >73% of healthcare spend 1. Audience (e.g. specialty) 3 is decided by Doctors1 2. Number of audience members 11:1 ROI 3. Type and number of modules I

  9. Slide 9: Land and Expand Sales Motion

    LAND AND EXPAND SALES MOTION 1 Land Initial Brands or Service Lines 2 Expand to Add’l Brands or Service Lines Service Service Brand Line Line 07 07 08 Service Service Service Brand Brand Brand Line Line Line 04 05 06 04 05 06 Service Service Service Service Brand Brand Brand Brand Line Line Line Lin

  10. Slide 10: Categories of Modules

    CATEGORIES OF MODULES Awareness Interactivity Peer Build brand equity and Replace face-to-face interactions Connect and build communicate key messages with digital alternatives professional relationships Proprietary 10

  11. Slide 11: Large & Growing Total Addressable Market

    LARGE & GROWING TOTAL ADDRESSABLE MARKET $18.5B $4.3B + $6.9B + $7.3B U.S. Pharmaceutical Marketing U.S. Health System U.S. Software Total to Medical Professionals1 Marketing and Staffing2 Telehealth3 1. Pharmaceutical Marketing TAM represents total annual marketing spend by Pharmaceutical Manufacture

  12. Slide 12: ~415 Rx Brands with $100M+ in U.S. Sales

    ~415 RX BRANDS WITH $100M+ IN U.S. SALES Estimated Doximity Share of HCP Marketing Budgets at Customers1 Est. Share of Total HCP Marketing Budgets1 <5% Current Potential Penetration Expansion Note: Each box represents one brand with $100M+ in U.S. sales >50% 20-50% 5-20% <5% No Revenue In Trailing 1

  13. Slide 13: Q2 Street Metrics

    Q2 STREET METRICS LAND & EXPAND 1 Number of Customers w/ $100k+ of Revenue Net Revenue Retention2 37% CAGR Subscription-Based 3 TTM Rev Growth 1. Refer to appendix for the definition of customers with trailing 12-month subscription revenue greater than $100,000. 2. Refer to appendix for the definition

  14. Slide 14: High Growth Revenue & Attractive Margin Profile

    HIGH GROWTH REVENUE & ATTRACTIVE MARGIN PROFILE Revenue1 Adj. EBITDA & Margin1,2 49% 43% CAGR 107% 44% CAGR 31% 23% 11% 3 3 1. Fiscal Year ended March 31. 2. Refer to appendix for the definition and non-GAAP reconciliation of Adjusted EBITDA and Adjusted EBITDA margin. 3. Fiscal Year 2023 is based on

  15. Slide 15: Founder-Led, Mission Driven

    FOUNDER-LED, MISSION DRIVEN 953 EMPLOYEES1 Jeff Tangney Shari Buck Dr. Nate Gross Anna Bryson CEO & Co-Founder Co-Founder CSO & Co-Founder CFO 1/3+ IN R&D1 Paul Jorgensen Jey Balachandran Joel Davis Jennifer Chaloemtiarana CRO CTO SVP Product General Counsel 1 As of September 30, 2022. 15 Proprietary

  16. Slide 16: Company Highlights

    COMPANY HIGHLIGHTS 1 Leading digital platform for doctors 2 Powerful network effects 3 Sustainable high-growth revenue & profitability 4 Veteran vertical team 5 Massive near-term market opportunity fueled by shift to digital Proprietary 16

  17. Slide 17: Appendix: Non-GAAP Financial Measures

    APPENDIX: NON-GAAP FINANCIAL MEASURES To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance:

  18. Slide 18: Appendix: Adjusted EBITDA & Margin Non-GAAP Reconciliation

    APPENDIX: ADJUSTED EBITDA & MARGIN NON-GAAP RECONCILIATION1 Year Ended March 31, TTM 2020 2021 2022 Q2 FY23 (in thousands) (in thousands) Net Income $29,737 $50,210 $154,783 $141,055 Adjustments: Acquisition and other related expenses 1,158 496 254 284 Stock-based compensation 2,353 7,252 31,442 40,

Doximity — Investor Presentation (November 2022) on 6ix